Treatment Action Campaign has written a letter to the minister of health raising concerns about some specifications in the ARV tender. The inclusion of FDC’s in the tender is welcomed but TAC would like for price to not be the only deciding factor when choosing which regimens to procure. FDC’s have been proven to be beneficial for improved adherence to treatment. FDCs make prescribing, dispensing and monitoring treatment easier for nurses and pharmacists.
TAC urges the Department of Health to intervene in the ARV tender process to ensure that FDCs will be preferred over mono-therapy formulations.